Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
Brain and Behavior · 2025
DOI: 10.1002/brb3.70221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Hüseyin Bahadır Şenol und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey. Hauptthemen laut MEDLINE: Oligonucleotides, Muscular Atrophy, Spinal, Kidney, Spinal Muscular Atrophies of Childhood. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Spinal muscular atrophy (SMA) is a motor neuron disease caused by mutations in the SMN1 gene. Nusinersen, an antisense oligonucleotide, has been shown to improve motor function in SMA patients. However, concerns regarding its renal safety remain as previous studies have linked similar treatments to renal toxicity.
Objective
The aim of this study was to evaluate the effects of the nusinersen treatment on platelet counts and renal functions, specifically urine protein excretion, in SMA patients and to estimate safe urinary protein levels before administration of each intrathecal injection.
Methods
This retrospective study examined data from 33 patients with SMA to assess the effects of nusinersen on motor functions and laboratory parameters including platelet count, serum creatinine, urine protein, and urine creatinine. Measurements were taken at baseline andprior to each maintenance dose, after the completion of four initial loading doses. The baseline values were compared between SMA Type 1 and Type 2 patients, while the changes in these values over time were analyzed within each group.
Results
No significant adverse effects on platelet counts or renal functions were observed. Urine creatinine and protein levels were significantly higher in SMA Type 2 patients compared to SMA Type 1 at baseline; these parameters remained stable in SMA Type 2 but increased significantly after the loading doses in SMA Type 1. Motor function improvements were observed in both groups, with the most significant gains in SMA Type 1 after the loading doses. Thus, improvement in motor functions was associated with increase in urine creatinine.
Conclusion
Nusinersen treatment did not cause significant renal toxicity or affect platelet counts. Urine creatinine levels may serve as a potential biomarker for assessing treatment response in SMA Type 1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Neurology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey.
- Department of Pediatric Nephrology, Denizli State Hospital, Denizli, Turkey.
ORCID-Profile: Hüseyin Bahadır Şenol, Gizem Yıldız, Ayşe İpek Polat, Adem Aydın, Ayşe Semra Hız, Alper Soylu, Uluç Yiş
Zitieren
APA
Bahadır Şenol, H., Yıldız, G., Polat, A. İ., Aydın, A., Hız, A. S., Soylu, A., & Yiş, U. (2025). Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy. Brain and Behavior. https://doi.org/10.1002/brb3.70221
Vancouver
Bahadır Şenol H, Yıldız G, Polat Aİ, Aydın A, Hız AS, Soylu A, et al. Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy. Brain and Behavior. 2025. doi:10.1002/brb3.70221
BibTeX
@article{Bahadrenol2025,
author = {Bahadır Şenol, Hüseyin and Yıldız, Gizem and Polat, Ayşe İpek and Aydın, Adem and Hız, Ayşe Semra and Soylu, Alper and Yiş, Uluç},
title = {Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70221}
}
EUVIMED